TY - JOUR
T1 - Long-term weight gain in children with craniopharyngioma
AU - Rovani, Sibylle
AU - Butler, Victoria
AU - Samara-Boustani, Dinane
AU - Pinto, Graziella
AU - Gonzalez-Briceno, Laura
AU - Quoc, Adrien Nguyen
AU - Vermillac, Gaëlle
AU - Stoupa, Athanasia
AU - Besançon, Alix
AU - Beltrand, Jacques
AU - Thalassinos, Caroline
AU - Flechtner, Isabelle
AU - Dassa, Yamina
AU - Viaud, Magali
AU - Arrom-Branas, Maria Beatriz
AU - Boddaert, Nathalie
AU - Puget, Stéphanie
AU - Blauwblomme, Thomas
AU - Alapetite, Claire
AU - Bolle, Stéphanie
AU - Doz, François
AU - Grill, Jacques
AU - Dufour, Christelle
AU - Bourdeaut, Franck
AU - Abbou, Samuel
AU - Guerrini-Rousseau, Léa
AU - Leruste, Amaury
AU - Beccaria, Kévin
AU - Polak, Michel
AU - Kariyawasam, Dulanjalee
N1 - Publisher Copyright:
© 2024 Oxford University Press. All rights reserved.
PY - 2024/5/1
Y1 - 2024/5/1
N2 - Objective: Adamantinomatous craniopharyngioma mainly affects children. Excessive weight gain is a major long-term complication. The primary objective of this study was to assess long-term weight changes in children treated for craniopharyngioma. The secondary objectives were to identify risk factors for excessive weight gain and to look for associations with hypothalamic damage by the tumour or treatment. Design: Single-centre retrospective cohort study. Method: Children managed for craniopharyngioma at our centre between 1990 and 2019 were included. The body mass index (BMI) standard deviation scores (SDS) at baseline and at last follow-up were compared. Univariate and multivariate analyses were performed in order to identify variables associated with the long-term BMI-SDS variation. Results: The 108 patients had a mean follow-up of 10.4 years. The mean BMI-SDS increase over time was 2.11 (P < .001) overall, 1.21 (P < .001) in the group without hypothalamic involvement by the tumour, and 1.95 (P < .001) in the group managed using intended hypothalamus-sparing surgery. The absence of hypothalamic involvement by the tumour or treatment was significantly associated with less weight gain (P = .046 and P < .01, respectively). After adjustment, factors associated with a BMI-SDS change greater than 2 were female sex (P = .023), tumour involving the hypothalamus (P = .04), and higher baseline BMI (P < .001). Conclusion: Clinically significant weight gain occurred in nearly all children treated for craniopharyngioma, including those whose hypothalamus was spared by the tumour and intentionally by treatment. However, hypothalamus integrity was associated with less weight gain. Despite hypothalamus-sparing strategies, hypothalamic obesity remains a major concern, indicating a need for novel treatment approaches.
AB - Objective: Adamantinomatous craniopharyngioma mainly affects children. Excessive weight gain is a major long-term complication. The primary objective of this study was to assess long-term weight changes in children treated for craniopharyngioma. The secondary objectives were to identify risk factors for excessive weight gain and to look for associations with hypothalamic damage by the tumour or treatment. Design: Single-centre retrospective cohort study. Method: Children managed for craniopharyngioma at our centre between 1990 and 2019 were included. The body mass index (BMI) standard deviation scores (SDS) at baseline and at last follow-up were compared. Univariate and multivariate analyses were performed in order to identify variables associated with the long-term BMI-SDS variation. Results: The 108 patients had a mean follow-up of 10.4 years. The mean BMI-SDS increase over time was 2.11 (P < .001) overall, 1.21 (P < .001) in the group without hypothalamic involvement by the tumour, and 1.95 (P < .001) in the group managed using intended hypothalamus-sparing surgery. The absence of hypothalamic involvement by the tumour or treatment was significantly associated with less weight gain (P = .046 and P < .01, respectively). After adjustment, factors associated with a BMI-SDS change greater than 2 were female sex (P = .023), tumour involving the hypothalamus (P = .04), and higher baseline BMI (P < .001). Conclusion: Clinically significant weight gain occurred in nearly all children treated for craniopharyngioma, including those whose hypothalamus was spared by the tumour and intentionally by treatment. However, hypothalamus integrity was associated with less weight gain. Despite hypothalamus-sparing strategies, hypothalamic obesity remains a major concern, indicating a need for novel treatment approaches.
KW - craniopharyngioma
KW - growth
KW - hypothalamic obesity
KW - paediatric patients
KW - weight
UR - http://www.scopus.com/inward/record.url?scp=85192626341&partnerID=8YFLogxK
U2 - 10.1093/ejendo/lvae044
DO - 10.1093/ejendo/lvae044
M3 - Article
C2 - 38662730
AN - SCOPUS:85192626341
SN - 0804-4643
VL - 190
SP - 363
EP - 373
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 5
ER -